| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Regular Articles |
From the Pathology Division*
and the
Biostatistics Division,
the
National Cancer Center Research Institute East; and the
Department of Surgery,
the National Cancer
Center Hospital East, Kashiwa, Chiba, Japan
Mitotic figures of fibroblasts are seen within invasive ductal carcinoma (IDC) of the breast. This suggests that the proliferative activity of fibroblasts may play an important role in IDC tumor progression. The purpose of this study was to examine whether the proliferative activity of fibroblasts can predict lymph node metastasis (LNM) or distant-organ metastasis (DOM) of IDCs. Two hundred four consecutive patients with IDC of the breast surgically treated at the National Cancer Center Hospital East constituted the basis of this study. Proliferative activity of fibroblasts was immunohistochemically evaluated by the mouse MIB-1 monoclonal antibody against Ki-67 antigen. The MIB-1 labeling index was the percentage of fibroblasts with positively stained nuclei, and fields for cell counting were selected in inner and outer areas within IDCs. In both areas, 300 fibroblasts were counted in each high-power field. The significance of proliferative activity of fibroblasts on LNM or DOM was compared with well-known prognostic parameters. Multivariate analyses demonstrated that a MIB-1 labeling index of more than 10% of fibroblasts in the inner area of IDCs significantly increased the relative risk of LNM and hazard rate of DOM (P < 0.001 and P = 0.007, respectively). The present study indicated that the metastatic ability of IDCs is closely dependent on proliferative activity of fibroblasts in the inner area.
This article has been cited by other articles:
 |
|
 |
|
  A. Gros, J. Martinez-Quintanilla, C. Puig, S. Guedan, D. G. Mollevi, R. Alemany, and M. Cascallo Bioselection of a Gain of Function Mutation that Enhances Adenovirus 5 Release and Improves Its Antitumoral Potency Cancer Res., November 1, 2008; 68(21): 8928 - 8937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Loebinger, E. K. Sage, and S. M. Janes Mesenchymal Stem Cells as Vectors for Lung Disease Proceedings of the ATS, August 15, 2008; 5(6): 711 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-P. Wu, M.-J. Young, C.-C. Tzeng, C.-R. Tzeng, K.-F. Huang, L.-W. Wu, and C.-Y. Chou A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer Carcinogenesis, June 1, 2008; 29(6): 1115 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Demicheli, E. Biganzoli, P. Boracchi, M. Greco, W. J.M. Hrushesky, and M. W. Retsky Allometric Scaling Law Questions the Traditional Mechanical Model for Axillary Lymph Node Involvement in Breast Cancer J. Clin. Oncol., September 20, 2006; 24(27): 4391 - 4396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Oken, C. L. Mercado, L. Memeo, and H. Hibshoosh Invasive Ductal Carcinoma with Fibrotic Focus: Mammographic and Sonographic Findings with Histopathologic Correlation Am. J. Roentgenol., August 1, 2005; 185(2): 490 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Cheng and L. M. Weiner Tumors and Their Microenvironments: Tilling the Soil: Commentary re: A. M. Scott et al., A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer. Clin. Cancer Res., 9: 1639-1647, 2003. Clin. Cancer Res., May 1, 2003; 9(5): 1590 - 1595. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
